Exact Sciences Mychart Patient Portal

WebWELCOME TO YOUR EXACT SCIENCES. PATIENT . PORTAL. View your secure health information, including test status and results, for all your Exact Sciences tests. Log in …

Test Description: The test is a laboratory-developed high-throughput real-time RT-PCR multiplexed assay developed by Exact Sciences Laboratories for the simultaneous qualitative detection of nucleic acid from COVID19, Influenza A and Influenza B virus in upper respiratory specimens. The assay is composed of two principal steps: (1) extraction of total nucleic acid (DNA and RNA) from patient specimens, (2) one-step reverse transcription and PCR amplification with COVID19 nucleocapsid (N) gene, Influenza A virus matrix (M1) gene, Influenza B virus nonstructural 2 (NS2) gene and human RPP30 (RP) gene transcripts with specific primers and probes.

Positive results are indicative of the presence of SARS-CoV-2, Influenza A and/or Influenza B. Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results are indicative of active infection but do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. The laboratory may be required to report positive results to the appropriate public health authority.

A false negative result may occur if a specimen is improperly collected, transported, or handled.

Insurance Bill – Patient’s insurance will be billed for services provided. Patient might have financial responsibility based on their insurance coverage.

Positive results are indicative of active infection but do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. The laboratory may be required to report positive results to the appropriate public health authority.